| scholarly article | Q13442814 |
| P50 | author | Gérard Reach | Q91737004 |
| Luc Martinez | Q91737006 | ||
| P2093 | author name string | René-Marc Flipo | |
| Pascal Maigret | |||
| Gaëlle Chenuc | |||
| Isabelle Elias-Billon | |||
| P2860 | cites work | Different domains - Different time preferences? | Q88591016 |
| Holistic psychosocial determinants of adherence to medication in people with type 2 diabetes | Q90384234 | ||
| Temporality in chronic diseases and adherence to long-term therapies: From philosophy to science and back | Q93344773 | ||
| A meta-analysis of the association between adherence to drug therapy and mortality | Q24548922 | ||
| The dual systems model: Review, reappraisal, and reaffirmation | Q26771640 | ||
| 2016 updated EULAR evidence-based recommendations for the management of gout | Q30248787 | ||
| A novel conceptual framework for understanding the mechanism of adherence to long term therapies. | Q30382635 | ||
| Treatment approaches and adherence to urate-lowering therapy for patients with gout | Q33597442 | ||
| A prescription for lifestyle change in patients with hyperuricemia and gout | Q34089976 | ||
| Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study | Q34410717 | ||
| Diabetic patients who smoke: are they different? | Q34628302 | ||
| The role of impulsive behavior in drug abuse | Q34792246 | ||
| Interrelationship of preventive actions in health and other areas | Q35098999 | ||
| A systematic review of interventions addressing adherence to anti-diabetic medications in patients with type 2 diabetes--impact on adherence | Q35116984 | ||
| Obedience and motivation as mechanisms for adherence to medication: a study in obese type 2 diabetic patients | Q35555613 | ||
| Quality of care indicators for gout management | Q35691678 | ||
| Adherence to placebo and mortality in the Beta Blocker Evaluation of Survival Trial (BEST) | Q35854669 | ||
| Evidence based guidelines or collectively constructed "mindlines?" Ethnographic study of knowledge management in primary care | Q35932822 | ||
| Four models of the physician-patient relationship | Q35965482 | ||
| Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations | Q36013873 | ||
| Alcohol consumption is inversely associated with adherence to diabetes self-care behaviours | Q36453704 | ||
| Quality of care for gout in the US needs improvement | Q36749515 | ||
| Adherence with urate-lowering therapies for the treatment of gout | Q37206942 | ||
| Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis | Q37221438 | ||
| Comparison of drug adherence rates among patients with seven different medical conditions. | Q37331773 | ||
| Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis | Q37503198 | ||
| Treatment adherence in patients with gout | Q37897018 | ||
| Delay discounting of gains and losses, glycemic control and therapeutic adherence in type 2 diabetes. | Q38805703 | ||
| Time and risk preferences and the use of asthma controller medication | Q39453861 | ||
| Patients' impatience is an independent determinant of poor diabetes control | Q39752930 | ||
| Hyperbolic discounting, the sign effect, and the body mass index | Q39899481 | ||
| A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy | Q40504910 | ||
| Adherence in diabetes: can we define it and can we measure it? | Q41445416 | ||
| Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout | Q44124046 | ||
| Obese women show greater delay discounting than healthy-weight women | Q47231775 | ||
| Adherence of patients with type 2 diabetes mellitus to medications: the role of risk preferences | Q47311437 | ||
| Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol | Q50063777 | ||
| The brief illness perception questionnaire. | Q50936509 | ||
| Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. | Q51608142 | ||
| Analysis of factors associated with seatbelt wearing among rear passengers in Malaysia. | Q51695471 | ||
| Maturation of limbic corticostriatal activation and connectivity associated with developmental changes in temporal discounting. | Q51900487 | ||
| Rate of adherence to urate-lowering therapy among patients with gout: a systematic review and meta-analysis. | Q52593279 | ||
| Adherence to Lipid-lowering Therapy and the Use of Preventive Health Services: An Investigation of the Healthy User Effect | Q59531972 | ||
| Disruption in time projection and non-adherence to long-term therapies | Q59794462 | ||
| [Assessment of antihypertensive compliance using a self-administered questionnaire: development and use in a hypertension clinic] | Q74259714 | ||
| Prevalence of the metabolic syndrome in individuals with hyperuricemia | Q80233374 | ||
| Independent impact of gout on mortality and risk for coronary heart disease | Q80795931 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P304 | page(s) | 1913-1926 | |
| P577 | publication date | 2019-11-07 | |
| P1433 | published in | Patient Preference and Adherence | Q7144972 |
| P1476 | title | Implication Of Character Traits In Adherence To Treatment In People With Gout: A Reason For Considering Nonadherence As A Syndrome | |
| P478 | volume | 13 |
Search more.